A clinic-based case-control study published in BMC Gastroenterology reports that patients with irritable bowel syndrome (IBS) have significantly lower serum ghrelin concentrations compared to healthy controls. The research, conducted in Northwestern Iran, suggests a potential link between this gut-derived peptide hormone and the severity of depressive symptoms in individuals suffering from IBS. The findings indicate that decreased ghrelin levels are associated with higher depression severity, highlighting the role of the gut-brain axis in the interaction between gastrointestinal and psychological symptoms.
The study aimed to investigate the association between serum ghrelin levels and depression severity in a specific patient population. IBS is a functional gastrointestinal disease that is commonly associated with psychological comorbidities. Ghrelin, a peptide hormone produced in the gut, participates in the regulation of the gut-brain axis. Because of its involvement in both gastrointestinal and emotional processes, researchers hypothesized that ghrelin might play a significant role in the emotional symptoms experienced by IBS patients. The primary objective was to determine if there was a measurable relationship between the concentration of ghrelin in the blood and the intensity of depression in these patients.
The research team enrolled 140 patients diagnosed with IBS based on Rome III criteria and 115 healthy controls who were matched for age and sex. To assess depression severity, the researchers utilized the Beck Depression Inventory-II (BDI-II), a standardized psychological tool. Statistical analyses included independent t-tests, analysis of variance (ANOVA), linear regression, and Pearson’s correlation analysis to evaluate the relationships between variables.
The results demonstrated that IBS patients had significantly lower ghrelin levels than the healthy control group, with a p-value of 0.001. When examining the relationship between depression severity and ghrelin levels, the study found that IBS patients with minimal, mild, moderate, or severe depressive symptoms exhibited lower ghrelin levels than controls with mild depression. The statistical significance for these comparisons was reported as P = 0.00. Furthermore, serum ghrelin levels were inversely correlated with IBS severity, with a correlation coefficient of r = -0.18 and a p-value of 0.001. This inverse correlation suggests that as IBS severity increases, ghrelin levels tend to decrease.
In addition to the correlation with IBS severity, serum ghrelin remained a significant predictor of BDI-II scores. The standardized beta coefficient was -0.442, with a p-value less than 0.001, indicating a strong predictive relationship between ghrelin levels and depression scores. In multivariable analysis, which adjusts for potential confounding factors, serum ghrelin remained independently associated with depression severity after adjustment for age, sex, and body mass index (BMI). This independent association strengthens the evidence that ghrelin levels are linked to depression severity in IBS patients, even when accounting for other demographic and physiological variables.
The study concludes that decreased ghrelin levels in IBS patients are linked to higher depression severity, which the authors identify as a major driver of disease severity. These findings suggest a potential role for the gut-brain axis in the complex interactions between IBS and psychological symptoms.
However, the authors emphasize that causal relationships cannot be inferred from this study due to its cross-sectional nature. The study design captures data at a single point in time, which limits the ability to determine whether low ghrelin levels cause depression or if depression leads to lower ghrelin levels. Further research is needed to clarify the underlying mechanisms and to establish causality.
The study was conducted by Masoomeh Dadkhah, Farhad Pourfarzi, and Somaieh Matin, and it was published in BMC Gastroenterology on November 10, 2026. The article is available open access.
Subject of Research: Association between serum ghrelin concentrations and depression severity in patients with irritable bowel syndrome: a clinic-based case–control study
Article Title: Association between serum ghrelin concentrations and depression severity in patients with irritable bowel syndrome: a clinic-based case–control study
Article References: Dadkhah, M., Pourfarzi, F., & Matin, S. (2026). Association between serum ghrelin concentrations and depression severity in patients with irritable bowel syndrome: a clinic-based case–control study. BMC Gastroenterology. https://doi.org/10.1186/s12876-026-05526-6
Image Credits: AI Generated
DOI: 10.1186/s12876-026-05526-6
Keywords: Association, between, serum, ghrelin, concentrations, depression, severity, patients, irritable, bowel, syndrome, clinic-based
News Source: Glenn Wilkins. (November 10, 2026). Lower Ghrelin Linked to Depression in IBS Patients. Scienmag.



